- Home
- STEW vs AUPH Comparison
STEW vs AUPH Comparison
Compare STEW & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STEW | AUPH |
|---|---|---|
| Founded | 1972 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | STEW | AUPH |
|---|---|---|
| Price | $17.89 | $15.54 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.25 |
| AVG Volume (30 Days) | 84.5K | ★ 1.7M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 3.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.44 | 0.55 |
| Revenue | N/A | ★ $265,808,000.00 |
| Revenue This Year | N/A | $21.22 |
| Revenue Next Year | N/A | $15.40 |
| P/E Ratio | ★ $10.34 | $28.19 |
| Revenue Growth | N/A | ★ 20.62 |
| 52 Week Low | $11.97 | $6.55 |
| 52 Week High | $14.94 | $16.48 |
Technical Indicators
Market Signals| Indicator | STEW | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 48.97 | 56.54 |
| Support Level | $17.96 | $15.41 |
| Resistance Level | $18.20 | $16.03 |
| Average True Range (ATR) | 0.19 | 0.51 |
| MACD | -0.01 | -0.17 |
| Stochastic Oscillator | 42.47 | 45.51 |
Price Performance
Historical ComparisonAbout STEW SRH Total Return Fund Inc.
SRH Total Return Fund, Inc. is a non-diversified closed-end management investment company. The company's investment objective is to seek total returns. Its fund utilizes a bottom-up, value-driven investment process to identify securities of good quality businesses trading below estimated intrinsic value. The Funds are available as an actively-managed closed-end fund, an actively managed ETF and a passively-managed ETF.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.